APA Guidelines Bundle

Treatment of Patients with Schizophrenia

APA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1303678

Contents of this Issue


Page 1 of 29

2 Introduction   ➤ The lifetime prevalence of schizophrenia is estimated to be approximately 0.7%. Worldwide, schizophrenia is one of the top 20 causes of disability.   ➤ Schizophrenia is also associated with increased mortality, with a shortened lifespan and standardized mortality ratios that are reported to be twofold to fourfold those in the general population. Individuals often have physical health comorbidities such as cardiovascular, respiratory, and infectious diseases and malignancies, particularly lung cancer.   ➤ About 4%–10% of persons with schizophrenia die by suicide, with rates that are highest among males in the early course of the disorder. Additional causes of death also include other unnatural events such as accidents and traumatic injuries.   ➤ Harms from therapeutic interventions may include: • adverse events that range from serious to less serious but affect tolerability to minor • negative effects of the intervention on quality of life • barriers and inconveniences associated with treatment • other negative aspects of treatment that may influence decision-making by the patient, the clinician or both.   ➤ The guideline statements should be implemented in the context of a person-centered treatment plan that includes evidence-based nonpharmacological and pharmacological treatments for schizophrenia.   ➤ See full text guideline for additional information.

Articles in this issue

Links on this page

Archives of this issue

view archives of APA Guidelines Bundle - Treatment of Patients with Schizophrenia